[ad_1]
“The ‘ongoing review’ of both vaccines started in February. Respectively, at the end of the second quarter, around June, it is planned to register both,” Gytis Andrulionis, head of IWT, told BNS on Friday.
This procedure is the first step in the approval of a vaccine in the Community.
Lithuania plans to buy 633,000 doses of the vaccine from Novavax and 1.4 million from CureVac. Russian Sputnik V vaccines are not planned.
The European Medicines Agency also released a “trial review” of the Russian Sputnik V vaccine in March.
According to G. Andrdrionis, this means that this vaccine can be approved at the same time as Novavax and CureVac.
“Novavax is probably the closest to approval. It is a very promising vaccine and clinical trials are going well, as far as I know,” said the IWT director.
According to G. Anddrulionis, Chinese vaccines from Sinovac, French and British companies Sanofi and GSK, and Italy’s ReiThera are also expected to be approved this year.
The Johnson & Johnson vaccine was approved by the European Medicines Agency on Thursday. The Pfizer and BioNTech, Moderna and AstraZeneca vaccines were approved some time ago.
In total, Lithuania has decided to buy about 10 million. doses of vaccines.
If you have any questions about the COVID-19 vaccine, please send them to our editorial staff by email. email address [email protected]
[ad_2]
